Drug giant Novartis AG has initiated a strategic review of its India-listed subsidiary Novartis India Ltd, amid reports that it is considering selling its 71% stake in the Indian business. A Novartis India spokesperson confirmed that Novartis AG has commenced this strategic review to assess its shareholding in the listed...
Novartis’ Cardiac Drug to Go Off-Patent in January
Swiss-American multinational pharmaceutical, Novartis AG's drug Vymada or Entresto used for patients with heart failure becomes off-patent in January, 2023 Heart failure is a progressive chronic syndrome characterized by a decrease in the functions of the heart and quality of life. 23 million people are affected by it worldwide, while...